The Philadelphia chromosome is formed by fusion of ABL (Ableson) proto-oncogene on chromosome 9 with the BCR (Breakpoint Cluster Region) gene on chromosome 22. The BCR/ABL fusion turns out to be positive in 90~95 % of CML (Chronic Myelogenous Leukemia) patients, 25 % of adult ALL (Acute Lymphocytic Leukemia) patients and 5 % of child ALL (Acute Lymphocytic Leukemia) sufferers. Depending on the breakpoint of the BCR gene, different types of BCR/ABL fusion genes (major type: b2a2, b3a2, minor type: e1a2, micro type: c3a2, etc.) are generated.
Chromosome tests usually have a high false negative rate as well as unexplainable mosaic forms of chromosome and require a sufficient amount of cells at division stage and require significant time and effort. Even though RT-PCR can be performed even with a limited amount of specimen, using conventional primers require additional nested PCR steps to detect BCR/ABL after initial RT-PCR.
Seeplex® Leukemia BCR/ABL detects 8 types of the BCR/ABL fusion gene simultaneously with only one PCR reaction after cDNA synthesis using DPO™ technology, which maximizes specificity and sensitivity.